Analysis of Post-Liver Transplant Hepatitis C Virus Recurrence Using Serial Cluster of Differentiation Antibody Microarrays

Wassim Rahman, Thomas Tu, Magdalena Budzinska, Pauline Huang, Larissa Belov, Jeremy S. Chrisp, Richard I. Christopherson, Fiona J. Warner, D. Scott Bowden, Alexander J. Thompson, David G. Bowen, Simone I Strasser, David Koorey, Alexandra F Sharland, Jean Y.H. Yang, Geoffrey W. Mccaughan, Nicholas A. Shackel

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)


Hepatitis C virus (HCV) reinfection of the liver allograft after transplantation is universal, with some individuals suffering severe disease recurrence. Predictive markers of recurrent disease severity are urgently needed. In this study, we used a cluster of differentiation (CD) microarray to predict the severity of HCV recurrence after transplantation. Methods The CD antibody microarray assays of live leukocytes were performed on peripheral blood taken in the first year after transplantation. The results were grouped into phases defined as; Pre-transplant (day 0), Early (day 3 to week 2), Mid (week 4 to week 10), and Late (week 12 to week 26). Hepatitis C virus severity was based on fibrosis stages in the first 2 years (F0-1 mild and F2-4 severe). Results Serial blood samples from 16 patients were taken before and after liver transplantation. A total of 98 assays were performed. Follow-up was 3 years or longer. Comparing recurrence severity, significantly greater numbers of CD antigens were differentially expressed on the pretransplant samples compared to any posttransplant timepoints. Five differentially expressed CD antigens before transplantation (CD27 PH, CD182, CD260, CD41, and CD34) were significantly expressed comparing severe to mild recurrence, whereas expression of only CD152 was significant in the late phase after transplantation. No relationship was observed between the donor or recipient interleukin-28B genotypes and HCV recurrence severity. Conclusions This study shows that circulating leukocyte CD antigen expression has utility in assessing recurrent HCV disease severity after liver transplantation and serves as a proof of principle. Importantly, pretransplant CD antigen expression is most predictive of disease outcome.

Original languageEnglish
Pages (from-to)e120-e126
Number of pages7
Issue number9
Publication statusPublished - 1 Sept 2015
Externally publishedYes

Cite this